Geographic Segments

12 Months Ended

Jun. 30, 2017

Geographic Segments

Geographic Segments

16.     Geographic Segments

Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer, autoimmune and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States. Immunomedics markets and sells LeukoScan® throughout Europe and in certain other countries outside the United States.

The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the years ended (in thousands):

	As of and for the year ended
	June 30, 2017
	United
	States		Europe		Total
Total assets	$	161,484	$	1,089	$	162,573
Property and equipment, net		5,166		79		5,245
Revenues		648		2,443		3,091
(Loss) income before taxes		(153,348)		103		(153,245)

	As of and for the year ended
	June 30, 2016
	United
	States		Europe		Total
Total assets	$	55,451	$	1,499	$	56,950
Property and equipment, net		3,895		74		3,969
Revenues		972		2,261		3,233
Loss before taxes		(63,688)		(502)		(64,190)

		As of and for the year ended
		June 30, 2015
		United
		States	Europe		Total
Total assets	$	104,168	$	1,612	$	105,780
Property and equipment, net		2,234		8		2,242
Revenues		3,054		2,599		5,653
(Loss) income before taxes		(48,192)		126		(48,066)